Condition (MeSH)
Carcinoma, Embryonal
ClinicalTrials.gov lists 35 trials for Carcinoma, Embryonal or a narrower condition beneath it. Children's Oncology Group has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
35 of the 35 trials are tagged with Carcinoma, Embryonal itself; the rest are tagged with a narrower condition beneath it.
When did Carcinoma, Embryonal trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2021 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2013 | 1 |
| 2007 | 3 |
| 2006 | 1 |
| 2005 | 1 |
| 2004 | 2 |
| 2003 | 4 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinoma, Embryonal trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 16 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |
| Not applicable | 4 |
| Observational | 1 |
How many Carcinoma, Embryonal trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 29 |
| Terminated | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinoma, Embryonal trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Children's Oncology Group | 4 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Medical Research Council | 2 |
| National Cancer Institute (NCI) | 2 |
| Eastern Cooperative Oncology Group | 1 |
Which drugs are being tested for Carcinoma, Embryonal? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 8 |
| Bleomycin | 7 |
| PEGFILGRASTIM | 3 |
| Cytoxan | 2 |
| Thiotepa | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cisplatin 1 | 10 |
| Etoposid | 10 |
| Ifosfamid | 9 |
| Filgrastime (G-CSF) | 8 |
| or carboplatin | 7 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Carcinoma, Embryonal trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutropenia | 43 | 1 |
| Vomiting | 16 | 3 |
| Febrile neutropenia | 15 | 2 |
| Nausea | 13 | 1 |
| Anemia | 12 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Carcinoma, Embryonal? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment. | The Journal of urology | 2013 | Yes |
| Wnt family proteins are secreted and associated with the cell surface. | Molecular biology of the cell | 1993 | No |
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Embryonal carcinoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Embryonal carcinoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Embryonal carcinoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Embryonal carcinoma | 180226 | Exact | Orphadata Science knowledge files, Product 1 |
| Embryonal carcinoma | 180226 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.